ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.

ישראל - עברית - Ministry of Health

organon pharma israel ltd., israel - betamethasone as dipropionate; betamethasone sodium phosphate - תרחיף להזרקה - betamethasone sodium phosphate 2 mg/ml; betamethasone as dipropionate 5 mg/ml - betamethasone - betamethasone - produces anti-inflammatory, anti rheumatic and anti-allergic action and is indicated for systemic and local therapy of acute and chronic corticosteroid-responsive disorders.

ישראל - עברית - Ministry of Health

sanofi israel ltd - amiodarone hydrochloride - תמיסה להזרקה - amiodarone hydrochloride 50 mg / 1 ml - amiodarone - amiodarone - corronary insufficiency, arrhythmias resistant to other treatments, wolf parkinson white syndrome.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - belimumab - אבקה להכנת תמיסה מרוכזת לעירוי - belimumab 120 mg - belimumab - belimumab - benlysta is indicated as add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (sle) with a high degree of disease activity (e.g positive anti dsdna and low complement) despite standard therapy.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - belimumab - אבקה להכנת תמיסה מרוכזת לעירוי - belimumab 400 mg - belimumab - belimumab - benlysta is indicated as add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (sle) with a high degree of disease activity (e.g positive anti dsdna and low complement) despite standard therapy.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - belimumab - תמיסה להזרקה - belimumab 200 mg / 1 ml - belimumab

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - atovaquone; proguanil hydrochloride - טבליות מצופות פילם - atovaquone 62.5 mg; proguanil hydrochloride 25 mg - proguanil, combinations - proguanil, combinations - prevention of malaria: for the prophylaxis of p.falciparum malaria, including in areas where chloroquine resistance has been reported. treatment of malaria: for the treatment of acute, uncomplicated p.flaciparum malaria. malarone has been shown to be effective in regions where the drugs chloroquine, halofantrine, mefloquine, and modiaquine may have unacceptable failure rates, presumably due to drug resistance.malarone is recommended for pediatric patients who weigh over 11 kg.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - atovaquone; proguanil hydrochloride - טבליות מצופות פילם - atovaquone 250 mg; proguanil hydrochloride 100 mg - proguanil, combinations - proguanil, combinations - prevention of malaria: for the prophylaxis of p.falciparum malaria, including in areas where chloroquine resistance has been reported. treatment of malaria: for the treatment of acute, uncomplicated p.flaciparum malaria. malarone has been shown to be effective in regions where the drugs chloroquine, halofantrine, mefloquine, and modiaquine may have unacceptable failure rates, presumably due to drug resistance.

ישראל - עברית - Ministry of Health

organon pharma israel ltd., israel - losartan potassium - טבליה - losartan potassium 50 mg - losartan - losartan - hypertension: ocsaar is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to ocsaar is not recommended. renal protection in type-2 diabetic patients with proteinuria: ocsaar is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. ocsaar is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrophy. the benefit of ocsaar on the primary deposite endpoint was lar

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - losartan potassium - טבליות מצופות פילם - losartan potassium 50 mg - losartan - losartan - hypertension: losartan is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to losartan is not recommended. renal protection in type-2 diabetic patients with proteinuria: losartan is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrophy. the benefit of losartan on the primary deposite endpoi